{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:08:45Z","timestamp":1790752125548,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2021R1I1A1A01055575"],"award-info":[{"award-number":["NRF-2021R1I1A1A01055575"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.canlet.2024.216714","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T21:24:28Z","timestamp":1708118668000},"page":"216714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma"],"prefix":"10.1016","volume":"588","author":[{"given":"Joonseok","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeyoun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Soo","family":"Jeun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-1597","authenticated-orcid":false,"given":"Stephen","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216714_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216714_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","article-title":"Advances in local therapy for glioblastoma \u2014 taking the fight to the tumour","volume":"18","author":"van Solinge","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.canlet.2024.216714_bib4","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2024.216714_bib5","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib6","series-title":"Human Gamma-Delta (\u03b3\u03b4) T Cell Therapy for Glioblastoma: A Novel Alternative to Overcome Challenges of Adoptive Immune Cell Therapy","author":"Choi","year":"2023"},{"key":"10.1016\/j.canlet.2024.216714_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-015-2037-1","article-title":"Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma","volume":"127","author":"Mendez","year":"2016","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib8","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27357","article-title":"Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7\/IL-15 response among high-grade glioma patients treated with radiation and temozolomide","volume":"3","author":"Ellsworth","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2024.216714_bib9","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.ijrobp.2020.12.004","article-title":"Effect of interleukin-7 on radiation-induced lymphopenia and its antitumor effects in a mouse model","volume":"109","author":"Byun","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2024.216714_bib10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-012-0210-4","article-title":"Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival","volume":"7","author":"Morre","year":"2012","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib11","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1002\/cam4.5467","article-title":"Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma","volume":"12","author":"Ahn","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2024.216714_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-021-03891-8","article-title":"Hematological adverse events in the management of glioblastoma","volume":"156","author":"Garcia","year":"2022","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib13","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/neuonc\/noac070","article-title":"Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib14","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"N.C.N.S.C. For the, immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216714_bib15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/neuonc\/not203","article-title":"Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial","volume":"16","author":"Bloch","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib16","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","article-title":"Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma","volume":"92","author":"Huang","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2024.216714_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijrobp.2018.01.069","article-title":"Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma","volume":"101","author":"Rudra","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2024.216714_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11060-019-03167-2","article-title":"Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma","volume":"143","author":"Kim","year":"2019","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13014-019-1256-6","article-title":"Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era","volume":"14","author":"Byun","year":"2019","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11060-019-03146-7","article-title":"Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients","volume":"143","author":"Hui","year":"2019","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib21","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/cam4.2159","article-title":"Dosimetry of the brain and hypothalamus predicting acute lymphopenia and the survival of glioma patients with postoperative radiotherapy","volume":"8","author":"Ye","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2024.216714_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jocn.2019.11.017","article-title":"The association between total lymphocyte count after concomitant chemoradiation and overall survival in patients with newly diagnosed glioblastoma","volume":"71","author":"Ahn","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.canlet.2024.216714_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14791\/btrt.2020.8.e12","article-title":"Effect of cumulative dexamethasone dose during concomitant chemoradiation on lymphopenia in patients with newly diagnosed glioblastoma","volume":"8","author":"Lee","year":"2020","journal-title":"Brain Tumor Res. Treat"},{"key":"10.1016\/j.canlet.2024.216714_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106162","article-title":"Pre-operative hematological markers as predictive factors for overall survival and progression free survival in glioblastomas","volume":"197","author":"Marini","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.canlet.2024.216714_bib25","article-title":"Impact of lymphopenia on survival for elderly patients with glioblastoma: a secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial","volume":"3","author":"Song","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.canlet.2024.216714_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00066-021-01855-5","article-title":"Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy","volume":"198","author":"Mapelli","year":"2022","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.canlet.2024.216714_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1000280","article-title":"Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients","volume":"12","author":"Hsu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib28","first-page":"1","article-title":"Clinical study on changes of peripheral blood immune function indicators in adults with newly diagnosed glioblastoma during the peri-radiotherapy period","author":"Huang","year":"2023","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.canlet.2024.216714_bib29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3349\/ymj.2022.0352","article-title":"Clinical outcomes of moderately hypofractionated concurrent chemoradiotherapy for newly diagnosed glioblastoma","volume":"64","author":"Kim","year":"2023","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.canlet.2024.216714_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770561","article-title":"Immunosuppression in glioblastoma: current understanding and therapeutic implications","volume":"11","author":"Himes","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib31","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1158\/0008-5472.CAN-05-3773","article-title":"Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma","volume":"66","author":"Fecci","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216714_bib32","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216714_bib33","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.4049\/jimmunol.132.3.1208","article-title":"Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors","volume":"132","author":"Elliott","year":"1984","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.216714_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00170940","article-title":"Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor","volume":"14","author":"Elliott","year":"1992","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1172\/JCI114719","article-title":"Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors","volume":"86","author":"Elliott","year":"1990","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2024.216714_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0165-5728(91)90096-P","article-title":"Human glioblastoma cell derived transforming growth factor-\u03b22: evidence for secretion of both high and low molecular weight biologically active forms","volume":"34","author":"Bodmer","year":"1991","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.canlet.2024.216714_bib37","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1158\/1078-0432.CCR-12-3314","article-title":"Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages","volume":"19","author":"Bloch","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216714_bib38","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/neuonc\/nou343","article-title":"Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model","volume":"17","author":"Chae","year":"2014","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216714_bib40","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/neuonc\/noq001","article-title":"Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo\/neg monocytes, tumor factors, and dexamethasone","volume":"12","author":"Gustafson","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1259\/0007-1285-9-107-695","article-title":"Radiation-induced lymphopenia","volume":"9","author":"Goodfellow","year":"1936","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.canlet.2024.216714_bib42","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/1097-0142(197709)40:3<1102::AID-CNCR2820400319>3.0.CO;2-0","article-title":"Lymphopenia caused by cranial irradiation in children receiving craniospinal radiotherapy","volume":"40","author":"Harisiadis","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216714_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood.V20.2.203.203","article-title":"Studies on lymphocytes. I. Lymphopenia produced by prolonged extracorporeal irradiation of circulating blood","volume":"20","author":"Cronkite","year":"1962","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216714_bib44","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.18632\/oncotarget.27564","article-title":"Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow","volume":"11","author":"Kapoor","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216714_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn6758","article-title":"Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma","volume":"15","author":"Ghosh","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216714_bib46","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.1995.13.4.910","article-title":"Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma","volume":"13","author":"Bleehen","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib47","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/bjc.1998.654","article-title":"O6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma","volume":"78","author":"Middleton","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216714_bib48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","article-title":"Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications","volume":"22","author":"Su","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1215\/15228517-4-1-39","article-title":"A phase II study of extended low-dose temozolomide in recurrent malignant gliomas","volume":"4","author":"Khan","year":"2002","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)","volume":"65","author":"Newlands","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.216714_bib51","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s002800050691","article-title":"Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma","volume":"40","author":"Bower","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2024.216714_bib52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","article-title":"Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons","volume":"23","author":"Mohan","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib53","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2176\/nmc.50.638","article-title":"Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment","volume":"50","author":"Ishikawa","year":"2010","journal-title":"Neurol. Med.-Chir."},{"key":"10.1016\/j.canlet.2024.216714_bib54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/333571a0","article-title":"Stimulation of B-cell progenitors by cloned murine interleukin-7","volume":"333","author":"Namen","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216714_bib55","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1182\/blood.V99.11.3892","article-title":"Interleukin-7: from bench to clinic","volume":"99","author":"Fry","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216714_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156049","article-title":"IL-7: comprehensive review","volume":"160","author":"Winer","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.canlet.2024.216714_bib57","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.V88.5.1887.1887","article-title":"Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7","volume":"88","author":"Bolotin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216714_bib58","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/blood.V97.6.1525","article-title":"Interleukin-7 restores immunity in athymic T-cell\u2013depleted hosts","volume":"97","author":"Fry","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216714_bib59","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.immuni.2008.11.002","article-title":"Homeostasis of naive and memory T cells","volume":"29","author":"Surh","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.216714_bib60","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1182\/blood-2012-06-437236","article-title":"Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation","volume":"120","author":"Perales","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216714_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/cid\/cis383","article-title":"Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I\/IIa randomized, placebo-controlled, multicenter study","volume":"55","author":"L\u00e9vy","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.canlet.2024.216714_bib62","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood-2015-05-645077","article-title":"Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia","volume":"127","author":"Sheikh","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216714_bib63","doi-asserted-by":"crossref","first-page":"963","DOI":"10.21873\/anticanres.11405","article-title":"The role of IL-7 in immunity and cancer","volume":"37","author":"Lin","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2024.216714_bib64","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","article-title":"Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas","volume":"69","author":"Ray-Coquard","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216714_bib65","doi-asserted-by":"crossref","first-page":"765","DOI":"10.7150\/jca.10471","article-title":"Interleukin-7 and interleukin-15 for cancer","volume":"5","author":"Zarogoulidis","year":"2014","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2024.216714_bib66","doi-asserted-by":"crossref","first-page":"10267","DOI":"10.3390\/ijms160510267","article-title":"Mechanism of action of IL-7 and its potential applications and limitations in cancer immunotherapy","volume":"16","author":"Gao","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216714_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/0008-5472.CAN-10-3198","article-title":"In vivo antitumor activity of a recombinant IL-7\/HGFbeta hybrid cytokine in mice","volume":"71","author":"Lai","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2024.216714_bib68","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.174.6.1511","article-title":"Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy","volume":"174","author":"Jicha","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2024.216714_bib69","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/annonc\/mdv173","article-title":"ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients","volume":"26","author":"Tr\u00e9dan","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib70","article-title":"The role of IL-7 and IL-7R in cancer pathophysiology and immunotherapy","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2024.216714_bib71","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-015-1841-y","article-title":"Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas","volume":"124","author":"Campian","year":"2015","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.canlet.2024.216714_bib72","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/pbc.26158","article-title":"Preoperative systemic levels of VEGFA, IL-7, IL-17A, and TNF-\u03b2 delineate two distinct groups of children with brain tumors","volume":"63","author":"Sand\u00e9n","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.canlet.2024.216714_bib73","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1158\/1078-0432.CCR-21-0947","article-title":"Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 T cells and enhances survival in mouse glioma models","volume":"28","author":"Campian","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216714_bib74","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cts.12800","article-title":"hIL-7-hyFc, A long-acting IL-7, increased absolute lymphocyte count in healthy subjects","volume":"13","author":"Lee","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.canlet.2024.216714_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085789","article-title":"Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice","volume":"9","author":"Gou","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2024.216714_bib76","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216714_bib77","article-title":"Immune evasion strategies of glioblastoma","volume":"3","author":"Razavi","year":"2016","journal-title":"Frontier. Surgery"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524001071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524001071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:39:13Z","timestamp":1760816353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524001071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":77,"alternative-id":["S0304383524001071"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216714","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216714"}}